United BioSource Corporation Selects Datalabs as Electronic Data Capture Technology Partner and Vendor
DataLabs, an innovative developer of Internet-based applications for clinical development, announced today that it has signed a technology development and preferred provider agreement with United BioSource Corporation (UBC), which provides science- and evidence-based services and information to the biopharmaceutical industry.
Irvine , Calif. -- June 13, 2005 -- DataLabs, an innovative developer of Internet-based applications for clinical development, announced today that it has signed a technology development and preferred provider agreement with United BioSource Corporation (UBC), which provides science- and evidence-based services and information to the biopharmaceutical industry. UBC and DataLabs are working together to deliver electronic data capture solutions specific for late stage clinical trials.
"UBC selected DataLabs based upon the advanced technology and open architecture of their software," said Chad Clark, Senior Vice President of Operations for United BioSource Corp. "UBC is focused on helping pharmaceutical companies provide scientific evidence to support the use of their products. DataLabs technology will help us deliver the high-quality evidence-based product development solutions that our clients have come to expect from UBC."
UBC is a global company focused on meeting the growing demand for evidence to support the use of pharmaceuticals, biologics, medical devices, and diagnostic technology. UBC's evidence-based product support provides clients in the biopharmaceutical, medical device, and diagnostics industries with the rigorous, scientific evidence necessary to demonstrate the effectiveness, safety, and economic value of their products.
"DataLabs is pleased to have been selected by UBC," said Jim Langford, president of DataLabs. "As a leader in providing late stage services to the biopharmaceutical industry, we believe our collaboration with UBC will greatly improve our capabilities in this rapidly expanding market segment."
DataLabs allows contract research organizations, biotech, pharmaceutical companies, and academic institutions to accelerate clinical trials with the DataLabsXC suite of software for clinical study design, electronic data capture and data management. Unlike traditional application service provider (ASP) models, DataLabsXC offers organizations the flexibility to adapt the software to unique specifications and conduct studies in a cost-effective manner. DataLabsXC, based on Microsoft platform technology, XML Web services, and the CDISC ODM standard, easily adapts to each institution's complex operating procedures and integrates easily with their existing technology systems.
About United BioSource Corporation
United BioSource Corporation (UBC) delivers evidence-based solutions to optimize the medical and commercial potential of pharmaceuticals, biotechnology, medical devices, and diagnostics. UBC is based in Bethesda, Maryland. For more information about UBC, visit www.unitedbiosource.com or call 240-644-0420.
About DataLabs
DataLabs is an innovative developer of Internet-based applications for clinical development that helps the biopharmaceutical industry accelerate clinical trials with proven software for study design, data capture and data management. Based on Microsoft platform technology, XML Web services and CDISC ODM standards, the DataLabsXC product suite adapts to established operating procedures and integrates easily with existing technology systems. As a result, DataLabsXC customers enjoy a low total cost of ownership and high return on investment. Major pharmaceutical companies, government entities, healthcare organizations and contract research organizations are currently realizing time and cost savings using DataLabsXC. DataLabs is based in Irvine, Calif. with East Coast offices in North Wales, Pa. For more information, please visit www.datalabs.com.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Phase III SELECT-GCA Trial Results Lead to FDA Approval of Rinvoq for Giant Cell Arteritis
April 30th 2025Rinvoq (upadacitinib) becomes the first oral JAK inhibitor approved by the FDA for the treatment of giant cell arteritis in adults, following robust data from the Phase III SELECT-GCA trial demonstrating its efficacy in achieving sustained remission and reducing glucocorticoid exposure.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
